In-depth analysis of data from the RAS-ALS study reveals new insights in rasagiline treatment for amyotrophic lateral sclerosis.

Joachim SchusterJens DreyhauptKarla MönkemöllerLuc DupuisStéphane DieterléJochen H WeishauptJan KassubekSusanne PetriThomas MeyerJulian GrosskreutzBerthold SchrankMatthias BoentertAlexander EmmerAndreas HermannDaniel ZellerJohannes PrudloAndrea S WinklerTorsten GrehlMichael T HenekaSiw JohannesenBettina GörickeSimon Witzel Johannes DorstAlbert C Ludolphnull null

Published in: European journal of neurology (2024)

genotype (Rs2283265) show a pronounced benefit from treatment with rasagiline, pointing to the opportunities precision medicine could open up for ALS patients in the future.

Keyphrases

amyotrophic lateral sclerosis
end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
prognostic factors
machine learning
big data
patient reported outcomes
current status